adjust estim five compani follow recent earn report
file mark chang cut ep forecast
lesser extent also updat model account
equiti offer dilut give incom ceo rainer blair bit
flexibl call u-shap recoveri gener align view
model updat adjust estim five compani coverag
univers follow recent earn file
buy lower ep assum ep break-even
core revenue declin rel dip april assum modest
recoveri may/jun dental offic begin reopen note last week
comment oral busi also april consist
commentari pt ep
buy expect diversifi portfolio deliv among resili core
growth tool year guidanc flat factor tailwind
certain area cphd pll cytiva factor contribut
beckman upcom serolog test expect eua approv soon longer term within
diagnost think cphd radiomet well-posit see acceler
instal base growth last posit impact
franchis meanwhil also like themat play vaccine/therapi
develop variou program underway pll and/or cytiva
work bioprocess account pro-forma
revenu pt ep also align sotp framework
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
becton dickinson co
ep reflect non-gaap ep exclud sbc expens amort discret item
pleas see import disclosur inform page report
pleas see import disclosur inform page report
danah corporationhistor project statement incomedollar million except per share amount fiscal year end decemb histor net product incom incom interest share share analysisgross research sg ebitda oper margin incom net omx y/i growth analysisnet incom danah corpor jefferi llc equiti research
pleas see import disclosur inform page report
becton dickinson companyhistor project statement incomedollar million except per share amount fiscal year end septemb histor net product incom expens dividend share share analysisgross research sg ebitda oper incom net growth analysisnet bcr net product gross research sg oper incom net dilut jefferi co equiti research
pleas see import disclosur inform page report
mettler-toledohistor project statement incomedollar million except per share amount fiscal year end decemb histor net product incom share share analysisgross sg oper incom net growth analysisnet sg oper net dilut mettler-toledo jefferi co equiti research
pleas see import disclosur inform page report
dentspli sironahistor project statement incom million except per share histor product incom share share analysi net pm gross sg ebitda oper incom net growth analysissal net preciou sg oper incom net dilut dentsply-sirona jefferi llc equiti research
pleas see import disclosur inform page report
nanthealth llc histor project statement incomedollar million except per share amount fiscal year end decemb histor cancer good expens expens incom equiti method share share ep ep non- excl analysi gross margin research sg oper net analysisnet research sg oper nanthealth jefferi llc equiti research
price target impli ev
ep ge accret
acceler synergi captur recent
sustain tailwind increas covid test
price target impli ev
core revenu growth
softer demand
instrument
price target impli ep
dhr dramat portfolio evolut escal
secular organ revenu growth profil
reduc enterpris oper volatil
consider exposur favor secular growth
dynam underway life scienc diagnost
market key invest merit view
see premium peer
justifi
mix scope potenti upsid ge deal
pleas see import disclosur inform page report
nopat compound-annual-growth-rate next decad
realiz bcr-relat cost synergi
price multipl ev
realiz bcr-relat cost synergi
price multipl ev
hospit volum disrupt second wave
price multipl ev
see compel defens larg cap hold
expect return msd/hsd core growth
accompani abil drive mid-teen ep growth
 beyond still support dividend
posit updat alari fda approv
pleas see import disclosur inform page report
op margin
share repurchas activ
nopat compound-annual-growth-rate next decad
price multipl ev
organ revenu growth
organ revenu growth
laboratory-rel organ revenu growth recov
op margin
share repurchas
price multipl ev
organ revenu growth
organ revenu growth
chines demand slower recov
price multipl ev
mtd profil among highest
life scienc research suppli univers leverag
improv metric consider given
superior price power highli scalabl oper
infrastructur strong asset util acumen
intensifi consum safeti regul emerg
share gain data analyt labx one click
pleas see import disclosur inform page report
